Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

AM. Oza, D. Cibula, AO. Benzaquen, C. Poole, RH. Mathijssen, GS. Sonke, N. Colombo, J. Špaček, P. Vuylsteke, H. Hirte, S. Mahner, M. Plante, B. Schmalfeldt, H. Mackay, J. Rowbottom, ES. Lowe, B. Dougherty, JC. Barrett, M. Friedlander,

. 2015 ; 16 (1) : 87-97.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze II, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15022909
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 25481791
DOI 10.1016/s1470-2045(14)71135-0
Knihovny.cz E-zdroje

BACKGROUND: The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with or without BRCA1 or BRCA2 mutations. The aim of this study was to assess the efficacy and tolerability of olaparib in combination with chemotherapy, followed by olaparib maintenance monotherapy, versus chemotherapy alone in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer. METHODS: In this randomised, open-label, phase 2 study, adult patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer who had received up to three previous courses of platinum-based chemotherapy and who were progression free for at least 6 months before randomisation received either olaparib (200 mg capsules twice daily, administered orally on days 1-10 of each 21-day cycle) plus paclitaxel (175 mg/m(2), administered intravenously on day 1) and carboplatin (area under the curve [AUC] 4 mg/mL per min, according to the Calvert formula, administered intravenously on day 1), then olaparib monotherapy (400 mg capsules twice daily, given continuously) until progression (the olaparib plus chemotherapy group), or paclitaxel (175 mg/m(2) on day 1) and carboplatin (AUC 6 mg/mL per min on day 1) then no further treatment (the chemotherapy alone group). Randomisation was done by an interactive voice response system, stratified by number of previous platinum-containing regimens received and time to disease progression after the previous platinum regimen. The primary endpoint was progression-free survival according to Response Evaluation Criteria in Solid Tumors version 1.1, analysed by intention to treat. Prespecified exploratory analyses included efficacy by BRCA mutation status, assessed retrospectively. This study is registered with ClinicalTrials.gov, number NCT01081951, and has been completed. FINDINGS: Between Feb 12 and July 30, 2010, 173 patients at 43 investigational sites in 12 countries were enrolled into the study, of whom 162 were eligible and were randomly assigned to the two treatment groups (81 to the olaparib plus chemotherapy group and 81 to the chemotherapy alone group). Of these randomised patients, 156 were treated in the combination phase (81 in the olaparib plus chemotherapy group and 75 in the chemotherapy alone group) and 121 continued to the maintenance or no further treatment phase (66 in the olaparib plus chemotherapy group and 55 in the chemotherapy alone group). BRCA mutation status was known for 107 patients (either at baseline or determined retrospectively): 41 (38%) of 107 had a BRCA mutation (20 in the olaparib plus chemotherapy group and 21 in the chemotherapy alone group). Progression-free survival was significantly longer in the olaparib plus chemotherapy group (median 12.2 months [95% CI 9.7-15.0]) than in the chemotherapy alone group (median 9.6 months [95% CI 9.1-9.7) (HR 0.51 [95% CI 0.34-0.77]; p=0.0012), especially in patients with BRCA mutations (HR 0.21 [0.08-0.55]; p=0.0015). In the combination phase, adverse events that were reported at least 10% more frequently with olaparib plus chemotherapy than with chemotherapy alone were alopecia (60 [74%] of 81 vs 44 [59%] of 75), nausea (56 [69%] vs 43 [57%]), neutropenia (40 [49%] vs 29 [39%]), diarrhoea (34 [42%] vs 20 [27%]), headache (27 [33%] vs seven [9%]), peripheral neuropathy (25 [31%] vs 14 [19%]), and dyspepsia (21 [26%] vs 9 [12%]); most were of mild-to-moderate intensity. The most common grade 3 or higher adverse events during the combination phase were neutropenia (in 35 [43%] of 81 patients in the olaparib plus chemotherapy group vs 26 [35%] of 75 in the chemotherapy alone group) and anaemia (seven [9%] vs five [7%]). Serious adverse events were reported in 12 (15%) of 81 patients in the olaparib plus chemotherapy group and 16 of 75 (21%) patients in the chemotherapy alone group. INTERPRETATION: Olaparib plus paclitaxel and carboplatin followed by maintenance monotherapy significantly improved progression-free survival versus paclitaxel plus carboplatin alone, with the greatest clinical benefit in BRCA-mutated patients, and had an acceptable and manageable tolerability profile. FUNDING: AstraZeneca.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15022909
003      
CZ-PrNML
005      
20150724095433.0
007      
ta
008      
150709s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(14)71135-0 $2 doi
035    __
$a (PubMed)25481791
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Oza, Amit M $u Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: amit.oza@uhn.ca.
245    10
$a Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial / $c AM. Oza, D. Cibula, AO. Benzaquen, C. Poole, RH. Mathijssen, GS. Sonke, N. Colombo, J. Špaček, P. Vuylsteke, H. Hirte, S. Mahner, M. Plante, B. Schmalfeldt, H. Mackay, J. Rowbottom, ES. Lowe, B. Dougherty, JC. Barrett, M. Friedlander,
520    9_
$a BACKGROUND: The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with or without BRCA1 or BRCA2 mutations. The aim of this study was to assess the efficacy and tolerability of olaparib in combination with chemotherapy, followed by olaparib maintenance monotherapy, versus chemotherapy alone in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer. METHODS: In this randomised, open-label, phase 2 study, adult patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer who had received up to three previous courses of platinum-based chemotherapy and who were progression free for at least 6 months before randomisation received either olaparib (200 mg capsules twice daily, administered orally on days 1-10 of each 21-day cycle) plus paclitaxel (175 mg/m(2), administered intravenously on day 1) and carboplatin (area under the curve [AUC] 4 mg/mL per min, according to the Calvert formula, administered intravenously on day 1), then olaparib monotherapy (400 mg capsules twice daily, given continuously) until progression (the olaparib plus chemotherapy group), or paclitaxel (175 mg/m(2) on day 1) and carboplatin (AUC 6 mg/mL per min on day 1) then no further treatment (the chemotherapy alone group). Randomisation was done by an interactive voice response system, stratified by number of previous platinum-containing regimens received and time to disease progression after the previous platinum regimen. The primary endpoint was progression-free survival according to Response Evaluation Criteria in Solid Tumors version 1.1, analysed by intention to treat. Prespecified exploratory analyses included efficacy by BRCA mutation status, assessed retrospectively. This study is registered with ClinicalTrials.gov, number NCT01081951, and has been completed. FINDINGS: Between Feb 12 and July 30, 2010, 173 patients at 43 investigational sites in 12 countries were enrolled into the study, of whom 162 were eligible and were randomly assigned to the two treatment groups (81 to the olaparib plus chemotherapy group and 81 to the chemotherapy alone group). Of these randomised patients, 156 were treated in the combination phase (81 in the olaparib plus chemotherapy group and 75 in the chemotherapy alone group) and 121 continued to the maintenance or no further treatment phase (66 in the olaparib plus chemotherapy group and 55 in the chemotherapy alone group). BRCA mutation status was known for 107 patients (either at baseline or determined retrospectively): 41 (38%) of 107 had a BRCA mutation (20 in the olaparib plus chemotherapy group and 21 in the chemotherapy alone group). Progression-free survival was significantly longer in the olaparib plus chemotherapy group (median 12.2 months [95% CI 9.7-15.0]) than in the chemotherapy alone group (median 9.6 months [95% CI 9.1-9.7) (HR 0.51 [95% CI 0.34-0.77]; p=0.0012), especially in patients with BRCA mutations (HR 0.21 [0.08-0.55]; p=0.0015). In the combination phase, adverse events that were reported at least 10% more frequently with olaparib plus chemotherapy than with chemotherapy alone were alopecia (60 [74%] of 81 vs 44 [59%] of 75), nausea (56 [69%] vs 43 [57%]), neutropenia (40 [49%] vs 29 [39%]), diarrhoea (34 [42%] vs 20 [27%]), headache (27 [33%] vs seven [9%]), peripheral neuropathy (25 [31%] vs 14 [19%]), and dyspepsia (21 [26%] vs 9 [12%]); most were of mild-to-moderate intensity. The most common grade 3 or higher adverse events during the combination phase were neutropenia (in 35 [43%] of 81 patients in the olaparib plus chemotherapy group vs 26 [35%] of 75 in the chemotherapy alone group) and anaemia (seven [9%] vs five [7%]). Serious adverse events were reported in 12 (15%) of 81 patients in the olaparib plus chemotherapy group and 16 of 75 (21%) patients in the chemotherapy alone group. INTERPRETATION: Olaparib plus paclitaxel and carboplatin followed by maintenance monotherapy significantly improved progression-free survival versus paclitaxel plus carboplatin alone, with the greatest clinical benefit in BRCA-mutated patients, and had an acceptable and manageable tolerability profile. FUNDING: AstraZeneca.
650    _2
$a intravenózní podání $7 D061605
650    _2
$a aplikace orální $7 D000284
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protinádorové látky $x aplikace a dávkování $x škodlivé účinky $7 D000970
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a protein BRCA1 $x genetika $7 D019313
650    _2
$a protein BRCA2 $x genetika $7 D024682
650    _2
$a karboplatina $x aplikace a dávkování $7 D016190
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a inhibitory enzymů $x aplikace a dávkování $x škodlivé účinky $7 D004791
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a mutace $7 D009154
650    _2
$a stupeň nádoru $7 D060787
650    12
$a lokální recidiva nádoru $7 D009364
650    _2
$a nádory cystické, mucinózní a serózní $x farmakoterapie $x enzymologie $x mortalita $x patologie $7 D018297
650    _2
$a nádory vaječníků $x farmakoterapie $x enzymologie $x genetika $x mortalita $x patologie $7 D010051
650    _2
$a paclitaxel $x aplikace a dávkování $7 D017239
650    _2
$a ftalaziny $x aplikace a dávkování $x škodlivé účinky $7 D010793
650    _2
$a piperaziny $x aplikace a dávkování $x škodlivé účinky $7 D010879
650    _2
$a poly(ADP-ribosa)polymerasy $x metabolismus $7 D011065
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
650    _2
$a PARP inhibitory $7 D000067856
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cibula, David $u General University Hospital, Prague, Czech Republic.
700    1_
$a Benzaquen, Ana Oaknin $u Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
700    1_
$a Poole, Christopher $u University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
700    1_
$a Mathijssen, Ron H J $u Erasmus MC Cancer Institute, Rotterdam, Netherlands.
700    1_
$a Sonke, Gabe S $u Netherlands Cancer Institute, Amsterdam, Netherlands.
700    1_
$a Colombo, Nicoletta $u University of Milan-Bicocca, European Institute of Oncology, Milan, Italy.
700    1_
$a Špaček, Jiří $u University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Vuylsteke, Peter $u Sainte-Elisabeth Hospital, Namur, Belgium.
700    1_
$a Hirte, Holger $u Juravinski Cancer Centre, Hamilton, ON, Canada.
700    1_
$a Mahner, Sven $u University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Plante, Marie $u Laval University, Quebec, Canada.
700    1_
$a Schmalfeldt, Barbara $u Technical University Munich, Munich, Germany.
700    1_
$a Mackay, Helen $u Princess Margaret Cancer Centre, Toronto, ON, Canada.
700    1_
$a Rowbottom, Jacqui $u AstraZeneca, Macclesfield, UK.
700    1_
$a Lowe, Elizabeth S $u AstraZeneca, Wilmington, DE, USA.
700    1_
$a Dougherty, Brian $u AstraZeneca, Waltham, MA, USA.
700    1_
$a Barrett, J Carl $u AstraZeneca, Waltham, MA, USA.
700    1_
$a Friedlander, Michael $u Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.
773    0_
$w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 16, č. 1 (2015), s. 87-97
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25481791 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150724095513 $b ABA008
999    __
$a ok $b bmc $g 1083248 $s 905902
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 16 $c 1 $d 87-97 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace